After several decades, therapeutic cancer vaccines now show signs of efficacy and potential
to help patients resistant to other standard-of-care immunotherapies, but they have yet to …

With the development and regulatory approval of immune checkpoint inhibitors and adoptive
cell therapies, cancer immunotherapy has undergone a profound transformation over the …

CircRNAs are a class of single-stranded RNAs with covalently linked head-to-tail topology.
In the decades since its initial discovery, their biogenesis, regulation, and function have …

Cancer elimination in humans can be achieved with immunotherapy that relies on T
lymphocyte-mediated recognition of tumor antigens. Several types of these antigens have …

Cancer is a complex disease whose outcome depends largely on the cross-talk between the
tumor and its microenvironment. Here, we review the evolution of the field of tumor …

Immunotherapy has emerged as an effective strategy for the prevention and treatment of a
variety of diseases, including cancer, infectious diseases, inflammatory diseases, and …

Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) has been
tested in advanced melanoma patients at various centers. We conducted a systematic …

Despite the many advances that have occurred in the field of vaccine adjuvants, there are
still unmet needs that may enable the development of vaccines suitable for more …

There are strong biologic and preclinical rationales for the development of therapeutic
cancer vaccines; however, the clinical translation of this treatment strategy has been …

Traditional aluminum adjuvants can trigger strong humoral immunity but weak cellular
immunity, limiting their application in some vaccines. Currently, various immunomodulators …